FDA accepts clinical trial application for new drug RK-01 for diabetes

type 2 diabetes is a global epidemic, mostly after the age of 35-40, accounting for more than 90 percent of people with diabetes, affecting more than 400 million people worldwidedays ago, ARKAYTherapeutics announced that the U.SFDA(accepting its new diabetes(IND) application for a new drug clinicaltrial (IND)about RK-01
RK-01 is a "first-in-class" oraldrug(combined for the treatment of type 2 diabetes)It contains three ingredients, metformin, valsartan, and celexibthe clinical trial will evaluate the safety, tolerability, and efficacy of RK-01 compared to metformin in newly diagnosed patients, and in obese patients with type 2 diabetes who cannot effectively control blood sugar with metformin aloneRK-01's unique formula adds thytan and ceresib to metformin, blocking several complementary inflammation and high blood sugar mechanisms that lead to the gradual deterioration of islet beta cell function, which is at the heart of the complex pathophysiology of type 2 diabetesis an angiotensin II receptor type 1 blocker that has been approved for the treatment of hypertension, andSerexib is a selective epoxyase-2 (Cox-2) inhibitor that has been approved for the treatment of arthritisactivation of renin-angiotensin system (RAS) and Cox-2 in beta cells is associated with complex pathophysiology of type 2 diabetesCox-2-derived prostatin PGE2 inhibits glucose-dependent insulin secretion (GDIS) mediated by GLP-1 agonists from beta cells Some of the current lyse drugs are GLP-1 agonists, but the methods used in existing therapies do not block damage to beta cell function caused by inflammation Rk-01, on the other hand, can provide long-lasting blood sugar control by maintaining or restoring beta cells, and even delay and prevent the use of insulin